학술논문
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Document Type
Article
Author
Source
In: Annals of Oncology . (Annals of Oncology, February 2022, 33(2):169-180)
Subject
Language
English
ISSN
15698041
09237534
09237534